OREGA Biotech specializes in the discovery of novel targets and the development of first-in-class monoclonal antibodies based immunotherapy for the treatment of cancer.
OREGA Biotech SAS
In July 2013, OREGA Biotech, signed a master service agreement with genOway, the biotechnology company dedicated to the development of genetically modified animal models.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/orega-biotech” connections=”true” suffix=””]
The pipeline of the company focuses on tumor microenvironment. It encompasses monoclonal antibodies targeting cancerrelated inflammation and tumor immune-evasion.
In Jan 2016, OREGA Biotech grants Innate Pharma, full worldwide rights to its program of first-in-class anti-CD39 checkpoint inhibitors. Under the terms of the agreement, OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales.
In May 2014, Orega Biotech completed its second round of financing through a private investment through investors including Inserm Transfert Initiative, OCTALFA, Rh_ne Alpes Cr_ation and SHAM. Also, In 2013, company received a 1.3 Mn grant from ANR-RPIB funding from the Agence Nationale pour la Recherche.